How have the trifecta of recent developments—associated, all-cause mortality reduction reported in ODYSSEY Outcomes, price reduction of PCSK9 inhibitors, and new AHA Guidelines—affected your approach to deploying these agents at the front lines?

How have the trifecta of recent developments—associated, all-cause mortality reduction reported in ODYSSEY Outcomes, price reduction of PCSK9 inhibitors, and new AHA Guidelines—affected your approach to deploying these agents at the front lines?

CLICK HERE FOR CME CREDIT

How have the trifecta of recent developments—associated, all-cause mortality reduction reported in ODYSSEY Outcomes, price reduction of PCSK9 inhibitors, and new AHA Guidelines—affected your approach to deploying these agents at the front lines?

Created by

CMEducation Resources IQ&A Cardiovascular Intelligence Zone | The Medical Cardiology, Interventional Cardiology, Lipid Medicine, Atherosclerosis and Diabetes Specialist's Perspective

Presenter

Christian Ruff, MD

Christian Ruff, MD

Christian Ruff, MD Principal Investigator, ENGAGE-AF Trial TIMI Group Director, General Cardiology Brigham and Women’s Hospital Assistant Professor of Medicine Harvard Medical School Boston, MA